<DOC>
	<DOCNO>NCT01028963</DOCNO>
	<brief_summary>The purpose study evaluate safety potential effectiveness CCX140-B subject Type 2 diabetes mellitus .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy CCX140-B Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>The primary objective study evaluate safety tolerability CCX140-B subject Type 2 diabetes mellitus ( T2DM ) base subject incidence adverse event . The secondary objective study include evaluation effect CCX140-B several measure effectiveness commonly use evaluation diabetes medication .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Key Diagnosed type 2 diabetes mellitus Must body mass index ≥25 &lt; 45 kg/m2 , body mass index ≥25 &lt; 28 kg/m2 , waist circumference must &gt; 94 cm men &gt; 80 cm woman Must stable dose metformin least 8 week prior randomization Hemoglobin A1c ( HbA1c ) 6.5 10.0 % inclusive fasting plasma glucose 135 270 mg/dL inclusive Screening Key Type 1 diabetes mellitus history diabetic ketoacidosis Received insulin treatment within 12 week randomization Received chronic ( 7 day ) systemic glucocorticoid treatment within 12 week randomization Received sulfonylurea , thiazolidinedione , exenatide , glucose lower treatment ( metformin ) within 8 week randomization Symptomatic congestive heart failure require prescription medication , clinically evident peripheral edema , poorlycontrolled hypertension ( systolic blood pressure &gt; 160 diastolic blood pressure &gt; 100 ) , history unstable angina , myocardial infarction stroke within 6 month randomization , chronic renal failure History presence druginduced myopathy , druginduced creatine kinase elevation , leukopenia ( WBC count &lt; 3.5 x 10 ( 9 ) /L ) History presence form cancer within 5 year prior randomization , exception excise basal cell squamous cell carcinoma skin , cervical carcinoma situ breast carcinoma situ excise resect completely without evidence local recurrence metastasis Fasting serum triglyceride &gt; 400 mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>